Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 28:14:3507-3517.
doi: 10.2147/OPTH.S271646. eCollection 2020.

Two-Year Multicenter Outcomes of iStent inject Trabecular Micro-Bypass Stents Combined with Phacoemulsification in Various Types of Glaucoma and Ocular Hypertension

Colin Clement  1   2   3   4 , Frank Howes  5 , Alexandros S Ioannidis  6 , Michael Shiu  7 , David Manning  8 , Jed Lusthaus  3   4   9 , Ridia Lim  3   10 , Simon E Skalicky  11 , Todd Goodwin  12
Affiliations

Two-Year Multicenter Outcomes of iStent inject Trabecular Micro-Bypass Stents Combined with Phacoemulsification in Various Types of Glaucoma and Ocular Hypertension

Colin Clement et al. Clin Ophthalmol. .

Abstract

Purpose: This multicenter study evaluated 2-year effectiveness and safety following implantation of two second-generation trabecular micro-bypass stents (iStent inject ®) with phacoemulsification.

Materials and methods: This was a retrospective study of iStent inject implantation with phacoemulsification by nine surgeons across Australia. Eyes had mild to advanced glaucoma (predominantly primary open-angle/POAG, appositional angle-closure/ACG, or normal-tension/NTG) or ocular hypertension (OHT), and cataract. Evaluations included intraocular pressure (IOP); medications; proportions of eyes with 0 or ≥2 medications, reduced/stable medications versus preoperative, and IOP ≤15 mmHg; visual acuity; cup-to-disc ratio (CDR); visual fields (VF); adverse events; and secondary surgery.

Results: A total of 340 eyes underwent surgery and had 24-month follow-up data. At 24 months, mean IOP decreased by 16% from 16.4±4.7 mmHg preoperatively to 13.7±3.1 mmHg (p<0.001), and 77% of eyes achieved IOP of ≤15 mmHg versus 49% preoperatively (p<0.001). Mean number of medications decreased by 67% to 0.49±0.95 versus 1.49±1.20 preoperatively (p<0.001), with 74% of eyes medication-free versus 25% preoperatively (p<0.001), and 14% of eyes on ≥2 medications versus 46% preoperatively (p<0.001). Medication burden was reduced or stable in 98% of eyes versus preoperative. Stratified analyses showed significant IOP and medication reductions across glaucoma subtypes (POAG, ACG, NTG, OHT): 13-22% for IOP (p<0.01 for all) and 62-100% for medication (p<0.001 for all). Favorable safety included few adverse events; stable CDR, VF, and visual acuity; and filtering surgery in only 8 eyes (2.4%) over 2 years.

Conclusion: This 340-eye multicenter dataset provides robust evidence of the safety and efficacy of iStent inject implantation with phacoemulsification, with significant and sustained IOP and medication reductions through 2 years. Results were similarly favorable across glaucoma subtypes (including POAG, ACG, NTG, OHT) and were attained across various glaucoma severities, clinical sites, and surgeons, highlighting the real-world versatility and utility of this treatment modality.

Keywords: MIGS; glaucoma; iStent inject; intraocular pressure; microinvasive glaucoma surgery; multicenter; second-generation.

PubMed Disclaimer

Conflict of interest statement

CC reports personal fees from Allergan, Glaukos, Alcon, Merck, Sharp, Dohme. FH reports personal fees from Glaukos. ASI is a consultant for Glaukos. DM reports personal fees from Glaukos, Allergan, and Alcon including being a consultant for Alcon. JL reports research grants from Sydney Eye Hospital Foundation, Glaukos, and Zeiss. RL reports personal fees from Allergan and is a consultant for Glaukos. SS reports honoraria as a consultant from Glaukos. TG reports personal fees from and serves in the advisory board for Glaukos. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Mean IOP through 24 months postoperative, all eyes (n=340).
Figure 2
Figure 2
Proportional analysis of IOP at 24 months vs preoperative, all eyes (n=340).
Figure 3
Figure 3
Mean number of medications through 24 months postoperative, all eyes (n=340).
Figure 4
Figure 4
Proportional analysis of medications at 24 months vs preoperative, all eyes (n=340).
Figure 5
Figure 5
IOP reduction by glaucoma subtype (p<0.01 for all).
Figure 6
Figure 6
Medication reduction by glaucoma subtype (p<0.001 for all).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013 - DOI - PubMed
    1. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(10108):2183–2193. doi:10.1016/S0140-6736(17)31469-1 - DOI - PubMed
    1. Jampel HD, Musch DC, Gillespie BW, et al. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am J Ophthalmol. 2005;140(1):16–22. doi:10.1016/j.ajo.2005.02.013 - DOI - PubMed
    1. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC; Tube Versus Trabeculectomy Study Group. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153:804–814. doi:10.1016/j.ajo.2011.10.024 - DOI - PMC - PubMed
    1. Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013;131(12):1573–1582. doi:10.1001/jamaophthalmol.2013.5059 - DOI - PubMed

LinkOut - more resources